Page 8 - Demo
P. 8
Summary: TECENTRIQ targets PD-L1 to restore antitumour T-cell activity
In the lymph node
In normal tissue
In the tumour microenvironment
⚫ Direct: Targets PD-L1 on TCs and tumour-infiltrating immune cells to reactivate T cells
⚫ Complete: Provides dual blockade of PD-1 and B7.1, which can reinvigorate suppressed T cells to kill
cancer cells (via PD-1) and can enhance T-cell priming in the lymph node (via B7.1)
⚫ Selective: Spares PD-L2 / PD-1 interactions, helping to minimise autoimmune reactions in normal tissue
1.Chen, et al. Clin Cancer Res 2012; 2.Herbst, et al. Nature 2014; 3.Powles, et al. Nature 2014;
4.Park, et al. Blood 2010;
5.Paterson, et al. J Immunol 2011; 6.Yang, et al. J Immunol 2011 7.Latchman, et al. Nat Immunol 2001;
8.Brown, et al. J Immunol 2003;
9.Matsumoto, et al.
10.Biochem Biophys Res Commun 2008;
11.Akbari, et al. Mucosal Immunol 2010 12.Schmid, et al. J Clin Oncol 2016 (Abstract 11506)
